The pandemic shined a light on the biotech and pharmaceutical business with their prices for shares reached new heights due to the.
The big pharmaceutical companies have performed well through 2022, even as other industries struggle in the confront of the crisis in living costs and the rising cost of living.
A broad exposure to the industry will allow investors in biotech stocks to benefit from the growing demand over time for healthcare services.
Pharma has experienced significant changes in the last few years.
Although the Covid vaccines were the subject of headlines the years of research beginning to bear fruit for major players such as AstraZeneca as well as GlaxoSmithKline.
However, with the threat of a recession on the horizon, can pharmaceutical companies be in a position to maintain their growth? Could it be an ideal moment to buy biotech companies which have seen their stock prices plummet?
Covid vaccine Covid vaccine has increased AstraZeneca’s profile globally and in February, it announced an all-time high in revenue comprising $1.8billion of the Covid vaccine as well as the sales of the acquisition of $39 billion of Alexion. The company also raised its dividend to the largest amount it has ever had in the past decade.
AstraZeneca is currently the second-largest FTSE 100 company by market size after it doubled its share price over five years. It is also a favorite among income funds, including Artemis as well as Columbia Threadneedle UK Equity Income Fund.
The big pharma companies represented by FTSE 100’s constituents AstraZeneca as well as GlaxoSmithKline have been performing well in the overall market downturn this year. The shares of both companies are up 28 percent and 8 per cent for the year to date according to Garry White, Charles Stanley’s chief investment analyst.
Sales of the Covid-19 vaccine are slowly easing, but the ease of pandemic restrictions has boosted sales for other vaccines. The sales of cancer drugs are growing and the biggest players have plenty of pipelines for promising new products that are in the process of being developed.’
GSK has also been performing very well. In the initial quarter, sales increased by 32 percent while operating profits grew by 65 percent.
However, it faces an uncertain road ahead following the disposal of Haleon’s consumer division Haleon that is been listed at the London Stock Exchange.
The demerger is likely to alter the structure of GSK in the process of becoming an all-purpose pharma company. The company’s consumer healthcare division was generally predictable, with a steady income , but its shares have already plummeted since Haleon’s debut.
The Haleon opening day trade was on the lower than expected For investors seeking an income that is more steady, it could be a good investment.
Fundamentally, it is a very attractive sector and company to gain exposure to, given its defensive nature at an era when volatility is disrupting markets according to Chris Beckett, head of equity research at Quilter Cheviot.
The business has established strong markets and brands in the areas of oral health as well as digestion health, pain relief as well as respiratory health, vitamins and digestive health. There is no reason to believe that they can’t be sustained.’
How recession-proof are pharmaceuticals?
In general , demand from investors has been fairly resilient in spite of the recession since they’re considered to be safer and have more defensive characteristics.
Ailsa Craig, joint chief investment manager for International Biotechnology Trust says: In times of downturn, food and healthcare are typically a top priority for consumers, and the demand for medical care doesn’t diminish. Actually, the number of people over 65 years old aged who are likely to require medical treatment is predicted to double by the coming years.
Therefore, even though insurance coverage might be reduced and causing some price pressures, particularly for non-essential treatment, overall the sales of pharmaceuticals, especially of medicines that treat critical ailments, are not likely to be significantly affected by a decline to economic expansion.’
Conglomerates of healthcare have been historically comprised of a variety of businesses that cover pharmaceuticals, consumer health as well as animal health. Some could even include medical device business.
There is a consensus that a large group of people will provide you with an even more secure portfolio. Consumer health is a defensive… Pharmaceuticals may appear defensive, but you have to buy more items because they lose exclusivity. There are more troughs and peaks, according to Andrew Duncan, senior equity analyst at Killick.
How can investors determine which ones are best investments to make?
Investors should seek out a company that has a good reputation for Research and Development (R&D) as well as a strong pipeline, and a track record for the pipeline’s delivery Duncan. Duncan. It is essential to have plenty of eggs in your basket.
“We consider the broad direction of the travel… We try for companies to provide into the realm of R&D. Tools and life sciences sector… there’s a demand for services , however we’re not relying on the performance of a particular prototype or experiment.’
Companies set to benefit from this market include the US-listed Thermofisher which is a specialist in scientific research and recently bought the business of clinical trials.
Is it the right moment to invest in biotech stocks that are volatile?
Biotech firms, located at the crossroads between tech and pharma have also been the recipients of the vaccination bounce.
After soaring in 2020, shares of biotech companies have plummeted in the wake of the shift away from stocks that are growing. In the meantime, the Nasdaq biotechnology index seen an unstable three-year period, reaching its peak in 2021 before an extended decline.
This overshooting and adjustment in performance is typical of biotech, but the overall trend has been positive, with an outperformance compared to that of the UK FTSE 100 over the last three years, Craig adds. Craig.
International Biotechnology Trust is unusual among investment trusts that focus on growth that pay a large dividend. The current yield of 5.01 percent.
The trust has a wide range of companies, with the majority of with a drug approval currently on the market. This includes Horizon Therapeutics, Incite and Neurocrine.
Although biotech is an interesting investment opportunity for investors, it’s extremely risky, and investors who purchase individual stocks are susceptible to extreme risks.
White states: “The present issue for businesses operating on the forefront in biotech lies with the fact that as with the research and development that is carried out in the more conventional technology sectors, they require a significant amount of money upfront to compete with for their R&D.
The revenues they earn from their products, despite the fact that they might be significant but are not likely to be realized in the foreseeable future. It’s all about “jam tomorrow”.
“This type of business is dependent on borrowing, and higher cost of borrowing today will mean less profit realised over the long run.
The quantity of their interest be required to pay now has an immediate impact on the value of these businesses within models used by City analysts. When interest rates rise the forecasts for future earnings and price goals are decreased.’
Biotech’s hottest product Oxford Nanopore has certainly suffered since its debut on the market in the year 2000. It’s dropped 32 percent since the date of its debut and is down 56 per cent over the course of the year.
In March, the company reported that its the annual loss jumped to more than PS100million due to the costs linked the IPO and share-based payouts. The company also suffered at the close of an agreement in partnership with the Department of Health and Social Care which provided rapid Covid tests.
White continues: “The future of healthcare is certain to be positive, with promising developments in areas such as gene therapy based on mRNA, mRNA-based vaccines and monoclonal antibody monoclonal.
The general mood towards the biotech industry is seasonal and the pressure to structurally improve the less sexy portion of the industry remains significant.
Inflation, rising interest rates and geopolitical instability add to the negative sentiment around these investments due to the time frame they have to earn profits which means they are long-term high risk assets.
“Negative elements that will impact the outlook of the sector’s outlook remain in place for a while. It is probable for Big Pharma, with its numerous product lines and diverse revenue streams, will continue to be the preferred choice of investors to invest in the sector for a while. At present, safety is the most important factor.’
Menu